Efficacy of Sildenafil oral spray for the treatment of erectile dysfunction in patients with type 2 diabetes mellitus and prediabetes

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Aim. To evaluate the results of using Sildenafil in the form of an oral spray (Gent) for the treatment of erectile dysfunction (ED) in men with type 2 diabetes mellitus (DM) and prediabetes.

Material and methods. A total of 60 patients were divided into two groups of 30 people. The group 1 included patients with prediabetes, while group 2 consisted of patients with type 2 DM. All men had proven ED. The severity of ED was assessed using the International Index of Erectile Function (IIEF-5). To assess the state of penile blood flow, all patients underwent Doppler ultrasound before and after treatment. Patients with prediabetes used Sildenafil in the form of oral spray (Gent) 25 mg (2 doses) 1 time per day for 1 month, patients with type 2 diabetes received 50 mg (4 injections) every other day for 1 month. In addition, most of the subjects took metformin and followed diet therapy.

Results. In patients of both groups, the administration of Sildenafil oral spray led to a decrease in body weight, waist circumference, a decrease in insulin and Hemoglobin A1C level without changing of hypoglycemic therapy in those with type 2 DM. In men with prediabetes, a decrease in fasting insulin levels was found. During treatment, half of the persons with impaired glucose metabolism had an increase in the testosterone level. According to IIEF-5, a decrease in the severity of ED in both groups of patients was seen. In men with prediabetes, the average IIEF-5 score increased from 15.98 to 21.57 points (p<0.05), while in patients with type 2 DM it improved from 12.18 to 18.44 points (p<0.05). Doppler ultrasound indicated a significant increase in the maximum systolic blood flow velocity and arterial resistivity index after treatment with Sildenafil oral spray in patients with both prediabetes and type 2 diabetes.

Conclusion. Sildenafil oral spray can be effectively used for the treatment of ED in men with type 2 DM and prediabetes.

Texto integral

Acesso é fechado

Sobre autores

D. Korenkov

FGBOU VO North-Western State Medical University named after I.I. Mechnikov

Autor responsável pela correspondência
Email: dkoren@mail.ru

Ph.D., MD, Professor of the Department of Urology of North-Western State Medical University named after I.I. Mechnikov

Rússia, Saint Petersburg

D. Tumanov

Clinic “Medexpert”; Network of Clinics “Medica”

Email: dkoren@mail.ru

Ph.D., MD, Chief of the Clinic “Medexpert”, Saint Petersburg, Russia; Chief Endocrinologist of the Network of Clinics “Medica”

Rússia, Saint Petersburg; Saint Petersburg

N. Kuprina

North-West Public Health Research Center

Email: nadin20-sun@yandex.ru

Сhief of the radiology department, Ultrasound physician, radiologist of the North-West Public Health Research Center

Rússia, Saint-Petersburg

Bibliografia

  1. Morgunova T.B., Glinkina I.V., Fadeev V.V. Prediabetes. Problems and solutions. Medical advice. 2021;12:220–227. Russian (Моргунова Т.Б., Глинкина И.В., Фадеев В.В. Преддиабет. Проблемы и пути решения. Медицинский совет. 2021;12:220–227).
  2. Golodnikov I.I. Prediabetes – what do we know about him? Effective pharmacotherapy. 2022;18(32):16–20. Russian (Голодников И.И. Предиабет – что мы о нем знаем? Эффективная фармакотерапия. 2022;18(32):16–20).
  3. Chernova M.O., Yesaulenko D.I., Rozhivanova E.R., etc. Clinical and epidemiological characteristics of hypogonadism syndrome in men with type 2 diabetes mellitus in the Russian Federation: a combined analysis of research data for the period 2005-2022. Diabetes mellitus. 2023;1(26):4–12. Russian (Чернова М.О., Есауленко Д.И., Роживанова Е.Р. и др. Клинико-эпидемиологические характеристики синдрома гипогонадизма у мужчин с сахарным диабетом 2 типа в Российской Федерации: объединенный анализ данных исследований за 2005–2022 гг. Сахарный диабет. 2023;1(26):4–12).
  4. Kupelian V., Shabsigh R., Araujo A. B., et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J. Urol. 2006;176:222–226. doi: 10.1016/s0022-5347(06)00503-9.
  5. Feldman H.A., Goldstein I., Harzichristou D.G., et al. Impotence and medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994;151:54–61. doi: 10.1016/s0022-5347(17)34871-1.
  6. Miner M., Nehra A., Jackson G. et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am JMed. 2014;127(3):174–182. doi: 11.1016/j.amjmed.2013.10.013.
  7. Jackson G., Nehra A., Miner M., et al. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J ClinPract. 2013;67(11):1163–1172. doi: 10.1111/ijcp.12200.
  8. Hatzichristou D. et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25:138–146. doi: 10.1111/j.1464-5491.2007.02338.x.
  9. Mazo E.B., Gamidov S.I. Erectile dysfunction. Monograph. M. 2004. 36–61. Russian (Мазо Е.Б., Гамидов С.И. Эректильная дисфунция. Монография. М. 2004, c. 36–61).
  10. Brunner G.A., Pieber T.R., Schattenberg S., et al. Erectile dysfunction in patients with type I diabetes mellitus. Wien Med Wochenschr. 1995;145(21):584–586.
  11. Bancroft J., Gutierrez P. Erectile dysfunction in men with and without diabetes mellitus: a comparative study. Diabet Med. 1996;13(1):84–89. doi: 10.1002/(sici)1096-9136(199601)13:1<84::aid-dia16>3.3.co;2-1.
  12. Mazo E.B., Gamidov S.I., Ovchinnikov R.I., Iremashvili V.V. Erectile dysfunction in patients with diabetes mellitus: modern methods of treatment. Pharmateca. 2004;5:83–87. Russian (Мазо Е.Б., Гамидов С.И., Овчинников Р.И., Иремашвили В.В. Эректильная дисфункция у больных сахарным диабетом: современные методы лечения. Фарматека. 2004;5:83–87).
  13. Schiel R., Muller U.A. Prevalence of sexual disorders in a selection-free diabetic population (JEVIN). Diabetes Res. Clin. Pract. 1999; 44:115–121. doi: 10.1016/s0168-8227(99)00012-1.
  14. Deutsch S., Sherman L. Previously unrecognized diabetes mellitus in sexually impotent men. JAMA. 1980; 44:2430–2432.
  15. Mihaylov M.K., Lobkarev O.A., Prokop’ev YA.V. The prevalence and structure of erecktile dysfunction and the nature of dynamic cavernosography in its diagnosis. Public health nd healthcare. 2008(1); 94–98.
  16. Abdullaev R.Ya, Marchenko V.G., MatsakYu.V. Capabilities of ultrasonography and doppler ultrasound in erectile dysfunction. Rad. therapy. 2007;2:127–131.
  17. Vydrin P.S., Kalinina S.N., Koren’kov D.G. The results of ultrasound dopplerograaphyof the penis in a patient before and after transurethral enucleation of benign prostatic hyperplasia. Urological statements. 2021;11(4):305–314. Doi: https//doi.org/10.17816/uroved89701.
  18. Alyaev Yu.G., Chaly M.E., Sinitsin V.E., Grigoryan V.A. Echodopplerography in urology: A guide for practicing physicians. Moscow: Littera, 2007. 168 p. Russian (Аляев Ю.Г., Чалый М.Е., Синицин В.Е., Григоряен В.А. Эходопплерограция в урологии: Руководство для практикующих врачей. Москва: Литтера, 2007. 168 c.).
  19. Morgunov L.Y. Review of the use of sildenafil in the treatment of erectile dysfunction in any combined pathology. RMZH. 2016; 8:488–490. Russian (Моргунов Л.Ю. Обзор применения силденафила в лечении эректильной дисфункции при любой сочетанной патологии. РМЖ. 2016;8:488–490).
  20. Akhvlediani N.D., Matyukhov I.P. The modern place of sildenafil in the treatment of erectile dysfunction. Urologiia. 2018;2:142–146. Russian (Ахвледиани Н.Д., Матюхов И.П. Современное место силденафила в лечении эректильной дисфункции. Урология. 2018;2:142–146).
  21. Gamidov S.I., Ovchinnikov R.I., Popova A.Yu. Sildenafil citrate in the treatment of men with erectile dysfunction. Urology. 2014;6:99–103. Russian (Гамидов С.И., Овчинников Р.И., Попова А.Ю. Силденафил цитрат в лечении мужчин с эректильной дисфункцией. Урология. 2014;6:99–103).
  22. Krivoborodov G.G., Zakharov K.A., Vasilyuk V.B. and others. Pharmacokinetic features of sildenafil in the form of a spray in healthy men, depending on the meal. Urology. 2020;5:41–47. Russian (Кривобородов Г.Г., Захаров К.А., Василюк В.Б. и др. Фармакокинетические особенности силденафила в форме спрея у здоровых мужчин в зависимости от приема пищи. Урология. 2020;5:41–47).
  23. Bacon C.G., Hu F.B., Giovannucci E. Association of Type and Duration of Diabetes With Erectile Dysfunction in a Large Cohort of Men. Diabetes Care. 2002;25(8):1417. doi: 10.2337/diacare.25.8.1458.
  24. Scranton R.E., Goldstein I., Stecher V.J. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med. 2013;10(2): 551–556. doi: 10.1111/j.1743-6109.2012.02998.x.
  25. Claes H.I.M., Van Poppel H. The use of sildenafil, tadalafil, and vardenafil in clinical practice. J Sex Med. 2004;1:42:Abstract O43.
  26. Nishlag E. Andrology. Men’s health and reproductive system dysfunction/Translated from English. Edited by E. Nishlag, G.M. Bere. M.: Medical Information Agency, 2005. 236 p. Russian (Нишлаг Э. Андрология. Мужское здоровье и дисфункция репродуктивной системы/ Пер. с англ. Под ред. Э. Нишлага, Г.М. Бере. М.: Медицинское информационное агентство, 2005. 236 с.).
  27. Hofer M. Color Duplex sonography. Practical guide. M.: Med. Lit., 2007. 108 p. Russian (Хофер М. Цветовая Дуплексная сонография. Практическое руководство. М.: Мед. лит., 2007. 108 с.).

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies